ArticleCells2020

Extracellular Matrix Features Discriminate Aggressive HER2-Positive Breast Cancer Patients Who Benefit from Trastuzumab Treatment.

Ilona Rybinska et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.